By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Dimerix Bioscience said today that it will help Takeda Cambridge Limited study G-protein coupled receptors (GPCR) that Takeda believes may be developed into drug compounds.

Under the agreement, Australia-based Dimerix will use its GPCR-HIT platform to form complexes called heteromers that can be used to screen for and profile compounds for Takeda Cambridge, which is a UK-based subsidiary of Japan's Takeda Pharmaceutical.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.